BioCentury
ARTICLE | Clinical News

Squamous NSCLC survival readouts at ASCO for Keytruda, Tecentriq

June 4, 2018 6:29 PM UTC

Merck & Co. Inc. (NYSE:MRK) and Roche (SIX:ROG; OTCQX:RHHBY) each reported survival data from Phase III trials of their checkpoint inhibitors Keytruda pembrolizumab and Tecentriq atezolizumab, respectively, as first-line treatment of squamous non-small cell lung cancer. Both companies reported data in weekend presentations at the American Society of Clinical Oncology (ASCO) meeting in Chicago.

In the KEYNOTE-407 trial, Keytruda plus chemotherapy led to a median overall survival (OS) of 15.9 months vs. 11.3 months for chemo alone (HR=0.64, 95% CI: 0.49, 0.85, p=0.0008). Median progression-free survival (PFS) was 6.4 months for Keytruda plus chemo vs. 4.8 months for chemo alone (HR=0.56, 95% CI: 0.45, 0.7, p<0.0001)...